Michael Williams
Byrd S. Leavell Professor of Medicine
University of Virginia · Charlottesville, United States
MCL translational researcher at UVA focused on molecular characterization, genomics, and MRD monitoring in mantle cell lymphoma.
A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas.
Oncology and therapy · Mar 7, 2026
Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.
Leukemia & lymphoma · Dec 1, 2025
Analysis of Real-World Progression and Insufficient Response Variables and Related Endpoints Among Patients with Non-Hodgkin Lymphoma.
Advances in therapy · Apr 1, 2025
Ibrutinib-Related Uveitis: A Case Series from Two Tertiary Centres in the United Kingdom.
Ocular immunology and inflammation · Dec 1, 2024
Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types.
PloS one · Jan 1, 2024